CHCL : DR SMITHS BIOTECH CEASES TO BE SUBSIDIARY AFTER NCLT APPROVES RESOLUTION PLAN

• NCLT Mumbai Bench-III approved Ananta Medicare's resolution plan for Dr. Smiths Biotech on September 23, 2026 • Entire existing equity share capital of Dr. Smith, including shares held by Cian Healthcare, extinguished and cancelled from October 23, 2026 • Company to receive nil consideration; cessation did not arise from any sale or disposal • Dr. Smith contributed nil revenue and ₹1.03 L total income (0.03% of consolidated ₹29.47 Cr) in FY26 • Dr. Smith net worth was negative ₹987 L against consolidated net worth of ₹8.54 Cr • SIDBI had claimed ₹8.55 Cr in the CIRP, of which ₹8.47 Cr was admitted

Cian Healthcare Ltd

Open attachment

← Back to feed